GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NGL Fine-Chem Ltd (BOM:524774) » Definitions » Cyclically Adjusted Revenue per Share

NGL Fine-Chem (BOM:524774) Cyclically Adjusted Revenue per Share : ₹365.94 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is NGL Fine-Chem Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NGL Fine-Chem's adjusted revenue per share for the three months ended in Mar. 2024 was ₹161.019. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹365.94 for the trailing ten years ended in Mar. 2024.

During the past 12 months, NGL Fine-Chem's average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of NGL Fine-Chem was 17.40% per year. The lowest was 17.40% per year. And the median was 17.40% per year.

As of today (2024-06-02), NGL Fine-Chem's current stock price is ₹2230.05. NGL Fine-Chem's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹365.94. NGL Fine-Chem's Cyclically Adjusted PS Ratio of today is 6.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NGL Fine-Chem was 14.73. The lowest was 3.59. And the median was 6.03.


NGL Fine-Chem Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for NGL Fine-Chem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGL Fine-Chem Cyclically Adjusted Revenue per Share Chart

NGL Fine-Chem Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 226.22 272.65 318.93 365.94

NGL Fine-Chem Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 318.93 332.11 342.50 355.21 365.94

Competitive Comparison of NGL Fine-Chem's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGL Fine-Chem's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NGL Fine-Chem's Cyclically Adjusted PS Ratio falls into.



NGL Fine-Chem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NGL Fine-Chem's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=161.019/153.0345*153.0345
=161.019

Current CPI (Mar. 2024) = 153.0345.

NGL Fine-Chem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 33.495 94.103 54.471
201409 37.489 96.780 59.280
201412 31.158 96.780 49.269
201503 40.859 97.163 64.354
201506 39.880 99.841 61.128
201509 37.224 101.753 55.984
201512 36.770 102.901 54.684
201603 42.057 102.518 62.781
201606 38.983 105.961 56.301
201609 33.881 105.961 48.933
201612 40.571 105.196 59.021
201703 41.813 105.196 60.828
201706 34.156 107.109 48.801
201709 46.465 109.021 65.223
201712 47.964 109.404 67.092
201803 51.773 109.786 72.168
201806 57.129 111.317 78.539
201809 62.978 115.142 83.704
201812 55.800 115.142 74.163
201903 68.850 118.202 89.139
201906 65.877 120.880 83.401
201909 60.270 123.175 74.880
201912 60.417 126.235 73.243
202003 54.467 124.705 66.840
202006 68.557 127.000 82.611
202009 110.643 130.118 130.130
202012 117.725 130.889 137.643
202103 115.957 131.771 134.669
202106 122.795 134.084 140.150
202109 126.847 135.847 142.896
202112 131.352 138.161 145.493
202203 132.846 138.822 146.447
202206 105.874 142.347 113.823
202209 109.643 144.661 115.989
202212 116.437 145.763 122.246
202303 126.069 146.865 131.365
202306 114.992 150.280 117.100
202309 129.780 151.492 131.101
202312 142.362 152.924 142.465
202403 161.019 153.035 161.019

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


NGL Fine-Chem  (BOM:524774) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NGL Fine-Chem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2230.05/365.94
=6.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NGL Fine-Chem was 14.73. The lowest was 3.59. And the median was 6.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NGL Fine-Chem Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of NGL Fine-Chem's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NGL Fine-Chem (BOM:524774) Business Description

Industry
Traded in Other Exchanges
Address
301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. The company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. Its product includes Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and Finished dosage form, of which maximum revenue is generated from Veterinary APIs. Its geographical segments include India, Europe, Asia Pacific, United States, and Rest of the world. The Group's business activities fall within a single business segment of pharmaceuticals.

NGL Fine-Chem (BOM:524774) Headlines

No Headlines